Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07061938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 8 months later Jan 20, 2027 → Sep 20, 2029
See other at-risk trials from Acepodia Biotech, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 20, 2027 to Sep 20, 2029 Show 7 more changesShow less
    • Enrollment increased: 30 → 34 participants
    • Trial sites expanded: 3 → 11 locations
    • Study completion pushed from Jun 20, 2027 to Sep 20, 2029
    • Trial arms changed: 1 → 2
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints revised (10)
    • Study description revised
  2. Study sites: 2 to 3v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary endpoint revised
    • Site details revised at 2 of 2 sites
    v3
  4. Start date: Aug 1, 2025 to Jan 1, 2026
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 32 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
Trial Details
NCT Number NCT07061938
Lead Sponsor Acepodia Biotech, Inc.
Conditions
(from sponsor)		 IgG4 Related Disease
Related terms Immunoglobulin G4-Related Disease
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov